(Reuters) – Bristol-Myers Squibb (NYSE:) Co expressed disappointment on Thursday with the opposition of its top shareholder to a $74 billion takeover of Celgene Corp (NASDAQ:), and said it would press on with what would be the largest pharmaceutical acquisition of all time.
Shares of the U.S. drugmaker were up 2 percent, while those of its smaller rival fell 8 percent before the opening bell, a day after asset manager Wellington Management said on Wednesday it did not support the deal to buy Celgene.
In a letter to employees, Bristol-Myers reiterated that the Celgene deal is the best path forward for the company and that it continued to believe strongly in the merits of the deal.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.